Ubs Group Ag Neurocrine Biosciences Inc Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Group Ag holds 316,927 shares of NBIX stock, worth $39.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

316,927

Previous 235,626 34.5%

Holding current value

$39.8 Million

Previous $32.5 Million 34.26%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $10.6 Million - $11.6 Million	81,301 Added 34.5%	316,927 $43.6 Million
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $12 Million - $13.2 Million	91,732 Added 63.75%	235,626 $32.5 Million
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $1.02 Million - $1.28 Million	9,655 Added 7.19%	143,894 $19 Million
Q3 2023 Nov 09, 2023	BUY	$94.02 - $117.1 $1.03 Million - $1.28 Million	10,938 Added 8.87%	134,239 $15.1 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $118,627 - $138,952	-1,325 Reduced 1.06%	123,301 $11.6 Million
Q1 2023 May 12, 2023	SELL	$94.11 - $123.02 $8.67 Million - $11.3 Million	-92,172 Reduced 42.52%	124,626 $12.6 Million
Q4 2022 Feb 08, 2023	BUY	$106.72 - $127.06 $6.9 Million - $8.22 Million	64,678 Added 42.52%	216,798 $25.9 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $6.29 Million - $7.37 Million	68,323 Added 81.53%	152,120 $16.2 Million
Q2 2022 Aug 10, 2022	SELL	$75.79 - $100.07 $10.7 Million - $14.2 Million	-141,449 Reduced 62.8%	83,797 $8.17 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $44,194 - $57,834	-610 Reduced 0.27%	225,246 $21.1 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $4.31 Million - $5.75 Million	54,141 Added 31.53%	225,856 $19.2 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $2.61 Million - $3 Million	30,328 Added 21.45%	171,715 $16.5 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $4.43 Million - $5.06 Million	49,514 Added 53.89%	141,387 $13.8 Million
Q1 2021 May 12, 2021	BUY	$87.57 - $119.4 $6.68 Million - $9.1 Million	76,245 Added 487.87%	91,873 $8.94 Million
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $48,408 - $60,339	-557 Reduced 3.44%	15,628 $1.5 Million
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $4.14 Million - $5.82 Million	-43,031 Reduced 72.67%	16,185 $1.56 Million
Q2 2020 Jul 31, 2020	BUY	$85.09 - $130.36 $776,020 - $1.19 Million	9,120 Added 18.21%	59,216 $7.23 Million
Q1 2020 May 01, 2020	SELL	$75.11 - $113.76 $1.87 Million - $2.84 Million	-24,952 Reduced 33.25%	50,096 $4.34 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $2.58 Million - $3.52 Million	-29,711 Reduced 28.36%	75,048 $8.07 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $6.12 Million - $7.41 Million	73,000 Added 229.86%	104,759 $9.44 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $856,694 - $1.08 Million	-11,859 Reduced 27.19%	31,759 $2.68 Million
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $7.22 Million - $9.54 Million	-104,174 Reduced 70.49%	43,618 $3.84 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $7.22 Million - $13.1 Million	105,626 Added 250.5%	147,792 $10.6 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $3.09 Million - $3.93 Million	31,256 Added 286.49%	42,166 $5.18 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $3.79 Million - $5.33 Million	-50,319 Reduced 82.18%	10,910 $1.07 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $2.85 Million - $3.48 Million	37,618 Added 159.32%	61,229 $5.08 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $1,229 - $1,629	21 Added 0.09%	23,611 $1.83 Million
Q3 2017 Nov 14, 2017	SELL	$47.97 - $61.28 $525,847 - $671,751	-10,962 Reduced 31.73%	23,590 $1.45 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-9,910 Reduced 22.29%	34,552 $1.59 Million
Q1 2017 Nov 14, 2017	BUY	N/A	44,462	44,462 $1.93 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account